NEW YORK (GenomeWeb News) – Microfluidics company RainDance Technologies said today that it has joined a French consortium to develop a microfluidic system for use in quantitative high-throughput screening of potential drug compounds.
 
In addition to the Lexington-Mass.-based company, the dScreen Consortium includes the drug-maker Sanofi-Aventis and the Institute for Science and Supramolecular Engineering at Louis Pasteur University of Strasbourg. The consortium was founded with assistance from the Alsace BioValley cluster.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.